Cancer chemotherapy and pharmacology
Journal
Overview
publication venue for
-
Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.
2023
-
Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma..
87.
2021
-
Pharmacokinetic and exposure-response analysis of pertuzumab in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer..
84.
2019
-
Neoadjuvant chemotherapy in patients with advanced endometrial cancer..
84.
2019
-
Exposure-response relationship of olaratumab for survival outcomes and safety when combined with doxorubicin in patients with soft tissue sarcoma..
83.
2018
-
A phase 1 study of ADI-PEG 20 and modified FOLFOX6 in patients with advanced hepatocellular carcinoma and other gastrointestinal malignancies..
82.
2018
-
Randomized phase 2 study of gemcitabine and cisplatin with or without vitamin supplementation in patients with advanced esophagogastric cancer..
82.
2018
-
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies..
81.
2018
-
A phase I study of intravenous artesunate in patients with advanced solid tumor malignancies..
81.
2018
-
Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment..
80.
2017
-
Carfilzomib and lenalidomide response related to VEGF and VEGFR2 germline polymorphisms..
80.
2017
-
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC)..
79.
2017
-
First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70..
77.
2015
-
Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies..
75.
2015
-
Alliance A091103 a phase II study of the angiopoietin 1 and 2 peptibody trebananib for the treatment of angiosarcoma..
75.
2015
-
Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors..
75.
2015
-
Investigation of novel circulating proteins, germ line single-nucleotide polymorphisms, and molecular tumor markers as potential efficacy biomarkers of first-line sunitinib therapy for advanced renal cell carcinoma..
74.
2014
-
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001)..
74.
2014
-
Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma..
73.
2013
-
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)..
73.
2013
-
Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers..
72.
2013
-
Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)..
72.
2013
-
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer..
72.
2013
-
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab..
72.
2013
-
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies..
71.
2013
-
The PPARγ agonist pioglitazone crosses the blood-brain barrier and reduces tumor growth in a human xenograft model..
71.
2013
-
Oblimersen in combination with temozolomide and albumin-bound paclitaxel in patients with advanced melanoma: a phase I trial..
71.
2012
-
A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)..
70.
2012
-
Phase II and gene expression analysis trial of neoadjuvant capecitabine plus irinotecan followed by capecitabine-based chemoradiotherapy for locally advanced rectal cancer: Hoosier Oncology Group GI03-53..
70.
2012
-
Population pharmacokinetic analysis of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in adult patients with solid tumors..
70.
2012
-
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors..
69.
2011
-
Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial..
69.
2011
-
A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors..
69.
2011
-
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma..
68.
2011
-
Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies..
68.
2011
-
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion..
68.
2011
-
Phase 1/pharmacology study of intraperitoneal topotecan alone and with cisplatin: potential for consolidation in ovarian cancer..
68.
2010
-
Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer..
68.
2010
-
Population pharmacokinetics of clofarabine and its metabolite 6-ketoclofarabine in adult and pediatric patients with cancer..
67.
2010
-
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer..
66.
2010
-
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol..
66.
2010
-
A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies..
66.
2010
-
A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors..
65.
2009
-
Safety and pharmacokinetic trial of docetaxel plus an Astragalus-based herbal formula for non-small cell lung cancer patients..
65.
2009
-
A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies..
64.
2009
-
Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors..
64.
2009
-
BCNU-sequestration by metallothioneins may contribute to resistance in a medulloblastoma cell line..
63.
2008
-
Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors..
63.
2008
-
NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells..
63.
2008
-
Phase II trial of sequential paclitaxel and 1 h infusion of bryostatin-1 in patients with advanced esophageal cancer..
62.
2008
-
Two peptides derived from ras-p21 induce either phenotypic reversion or tumor cell necrosis of ras-transformed human cancer cells..
62.
2007
-
Influence of carboplatin infusion on osteosarcoma blood flow..
62.
2007
-
Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors..
61.
2007
-
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors..
59.
2006
-
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer..
58.
2006
-
Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes..
57.
2005
-
Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer..
57.
2005
-
A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors..
57.
2005
-
Phase I study of green tea extract in patients with advanced lung cancer..
55.
2004
-
Enzyme expression profiles suggest the novel tumor-activated fluoropyrimidine carbamate capecitabine (Xeloda) might be effective against papillary thyroid cancers of children and young adults..
53.
2004
-
Pharmacokinetics of S-1, an oral formulation of ftorafur, oxonic acid and 5-chloro-2,4-dihydroxypyridine (molar ratio 1:0.4:1) in patients with solid tumors..
52.
2003
-
A phase I trial of perillyl alcohol in patients with advanced solid tumors..
51.
2003
-
Population pharmacokinetics of the novel anticancer agent KRN7000..
49.
2002
-
Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer..
49.
2001
-
ST1571, a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia: validating the promise of molecularly targeted therapy..
48 Suppl 1.
2001
-
A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility..
46.
2000
-
SEREX analysis of gastric cancer antigens..
46 Suppl.
2000
-
Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis..
45.
2000
-
Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion..
40.
1997
-
Phase II trial of chloroquinoxaline sulfonamide (CQS) in patients with stage III and IV non-small-cell lung cancer..
40.
1997
-
Tubulin from paclitaxel-resistant cells as a probe for novel antimicrotubule agents..
40.
1997
-
Clinical and pharmacology study of chloroquinoxaline sulfonamide given on a weekly schedule..
35.
1995
-
Clinical pharmacology of cytarabine in patients with acute myeloid leukemia: a cancer and leukemia group B study..
36.
1995
-
Modulation of all-trans retinoic acid pharmacokinetics by liarozole..
34.
1994
-
Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy..
31.
1993
-
Pharmacokinetics of ara-C and ara-U in plasma and CSF after high-dose administration of cytosine arabinoside..
29.
1992
-
Phase II study of ACNU as second-line treatment in small-cell lung cancer. EORTC Lung Cancer Cooperative Group..
29.
1992
-
Phenotypic analysis of 1-B-D-arabinofuranosylcytosine deamination in patients treated with high doses and correlation with response..
30.
1992
-
Membrane glycoprotein changes associated with anthracycline resistance in HL-60 cells..
28.
1991
-
Mitomycin C, teniposide, and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung..
28.
1991
-
Phase II study of ACNU in non-small-cell lung cancer: EORTC study 08872..
28.
1991
-
Epirubicin and ifosfamide in patients with refractory breast cancer and other metastatic solid tumours..
26 Suppl.
1990
-
Phase II study of divided-dose vinblastine in advanced breast cancer patients..
21.
1988
-
Etoposide in prostatic cancer: experimental studies and phase II trial in patients with bidimensionally measurable disease..
18.
1986
-
Phase I/II trial of intravesical methotrexate for superficial bladder tumors..
18.
1986
-
Treatment of blastic transformation of chronic myelogenous leukemia with mitoxantrone..
17.
1986
-
Phase-II trial of 4-demethoxydaunorubicin (DMDR) for advanced hypernephroma..
14.
1985
-
Phase-II trial of 1,2-diaminocyclohexane (4-carboxyphthalato) platinum (II) (DACCP) in non-small cell lung cancer..
12.
1984
-
Combination chemotherapy for the treatment of Hodgkin's disease in relapse. Results with lomustine (CCNU), melphalan (Alkeran), and vindesine (DVA) alone (CAD) and in alternation with MOPP and doxorubicin (Adriamycin), bleomycin, and vinblastine (ABV)..
11.
1983
-
Intrathecal cytosine arabinoside for the treatment of meningeal metastases from malignant brain tumors and systemic tumors..
8.
1982
-
Phase II trial of VP16-213 in non-small cell lung cancer (NSCLC)..
7.
1982
-
Metformin and pancreatic cancer: Is there a role?
2016
-
Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors.
2014
Identity
ISO Abbreviation
-
Cancer Chemother Pharmacol
Linking ISSN
International Standard Serial Number (ISSN)
Electronic International Standard Serial Number (EISSN)